MoUs to Strengthen Drug Quality, Research and Patient Safety
Under the leadership of Prime Minister Shri Narendra Modi, the IPC signed two Memoranda of Understanding on 24 April 2026 – one with the PMBI and another with the NIPER Hajipur. The agreements aim to improve drug quality, expand pharmacovigilance and promote rational use of medicines across the country.
Key Developments
- PMBI will forward randomly selected batches of medicines sold at PMBJKs to IPC for stringent quality testing.
- Both agencies will promote the NFI in all Jan Aushadhi stores to ensure rational drug use.
- IPC and PMBI will display the PvPI QR code and the toll‑free helpline (1800‑180‑3024) at every PMBJK, encouraging reporting of ADR and strengthening patient safety.
- Joint sensitisation, awareness and training programmes will be organised for pharmacists on rational drug use, ADR reporting and the role of pharmacists in safeguarding public health.
- IPC‑NIPER collaboration will focus on research on impurity profiling, especially genotoxic impurities, and on developing analytical methods and reference standards for biologics, biosimilars and emerging cell‑ and gene‑therapy products.
- Faculty exchange, shared use of advanced analytical instrumentation, internships, fellowships and joint publications will be facilitated between the two institutions.
Important Facts
The MoUs were signed by the Indian Pharmacopoeia Commission and the Pharmaceuticals & Medical Devices Bureau of India, both under the Ministry of Health and the Ministry of Chemicals and Fertilizers respectively. NIPER Hajipur is an autonomous institute under the Department of Pharmaceuticals. The agreements cover quality testing, pharmacopoeial standard setting, capacity building, and creation of reference standards for emerging therapies.
Exam Relevance
These initiatives illustrate the government's multi‑pronged approach to health governance – a frequent topic in GS III (Health, Social Justice and Welfare). Understanding the roles of bodies like IPC, PMBI and NIPER helps candidates answer questions on drug regulation, public‑health infrastructure and the promotion of affordable medicines.
Way Forward
Effective implementation will require systematic sampling of Jan Aushadhi medicines, robust laboratory capacity at IPC, and widespread awareness among pharmacists about PvPI. Strengthening research on genotoxic impurities will align India with global safety norms. Continuous monitoring, periodic audits and scaling up of training programmes will ensure that the objectives of the MoUs translate into tangible improvements in drug quality and patient safety across the nation.